Biomaterial to Counteract Ridge Reduction Following the Removal of Multiple Adjacent Teeth.
Launched by INSTITUTE FRANCI · Sep 12, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help prevent bone loss in the jaw after multiple teeth are removed. When teeth are taken out, the bone around the teeth can shrink, which can lead to problems for future dental implants. In this study, researchers are looking at whether using special materials called Bio-Oss Collagen and Bio-Gide can help keep the bone strong and healthy after tooth extractions.
To participate in this trial, you need to have healthy extraction sites, which means the area where the teeth were taken out should be intact, with some specific conditions about the bone structure. People with untreated severe tooth decay, uncontrolled gum disease, or certain health conditions that could affect healing are not eligible. If you join the study, you can expect to receive dental implants and the study materials, and you’ll need to return for follow-up appointments to monitor your progress. This trial is currently recruiting participants of all ages, so if you think you might qualify, it could be a good opportunity to help advance dental care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:intact extraction sockets following removal of the natural teeth defined by:
- • a marginal dehiscence defect of any of the facial bone walls of 3 mm
- • no facial fenestration present in the apical of the marginal bone crest
- Exclusion Criteria:
- • untreated rampant caries and uncontrolled periodontal disease
- • uncontrolled diabetes or any other systemic or local disease or condition that would compromise post-operative healing
- • unable or unwilling to return for follow-up or unlikely to be able to comply with study procedures according to investigators judgement.
About Institute Franci
Institute Franci is a leading clinical research organization dedicated to advancing medical science through innovative trial design and execution. With a strong focus on patient-centered research, the institute collaborates with pharmaceutical and biotechnology companies to facilitate the development of new therapies. Leveraging state-of-the-art methodologies and a robust network of clinical sites, Institute Franci ensures rigorous adherence to regulatory standards while prioritizing safety and efficacy. Committed to fostering collaboration among researchers, healthcare professionals, and patients, the institute aims to accelerate the delivery of transformative treatments to the market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials